PHARMATEK

RETATRUTIDE PEN

RETATRUTIDE PEN

Retatrutide Pen by Pharmatek is a next-generation prefilled autoinjector pen harnessing triple receptor agonist technology (GIP, GLP-1, and Glucagon). Engineered for maximum dosing accuracy and convenience in metabolic regulation protocols, it synergistically drives lipolysis, appetite suppression, and elevated energy expenditure.

Descripción

Retatrutide Pen by Pharmatek represents the pinnacle of therapeutic advances in metabolic health and body recomposition. By simultaneously targeting all three major metabolic peptide receptors (GIP, GLP-1, and Glucagon), this compound not only regulates insulin secretion and slows gastric emptying, but also actively increases thermogenesis and hepatic fat oxidation.

Delivered in an ergonomic multidose dial-a-dose pen device, Retatrutide Pen guarantees clean, virtually painless, and highly accurate administration without requiring manual reconstitution. Its turn-key format ensures maximum patient compliance and biological stability.

  1. General Information
  • Brand Name: Retatrutide Pen Pharmatek.
  • Active Ingredient: Retatrutide (Triple GIP / GLP-1 / Glucagon Receptor Agonist).
  • Presentation: Prefilled multidose autoinjector pen / liquid cartridge.
  • Route of Administration: Weekly Subcutaneous (S.C.) injection.
  1. Composition

Each prefilled pen contains:

  • Retatrutide Solution: Pharmaceutical-grade stabilized liquid formulation.
  • Excipients: Sodium phosphate, phenol, sodium chloride, and water for injection.
  1. Pharmacological Properties & Benefits
  • Triple Receptor Agonism: Concurrent engagement of GIP, GLP-1, and Glucagon pathways for unparalleled weight and metabolic control.
  • Enhanced Energy Expenditure: Glucagon receptor stimulation boosts basal metabolic rate and direct lipid oxidation.
  • Precision Pen Device: Dial-a-dose mechanism ensures exact dosing with microfine needles.
  • Central Appetite Suppression: Optimizes satiety signals and Delays gastric emptying.
  1. Usage & Storage
  • Administration: Inject subcutaneously once weekly into the abdomen, thigh, or upper arm.
  • Unopened Storage: Store refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze.
  • In-Use Storage: May be stored at room temperature (<25°C) or refrigerated for up to 30 days away from direct light.
  1. Warnings & Safety
  • Supervised Protocol: High-potency metabolic agent. Intended for use under professional oversight.
  • Gradual Titration: Gradual dose escalation is recommended to minimize gastrointestinal adaptation side effects.
  • Contraindications: Do not use in patients with personal/family history of Medullary Thyroid Carcinoma or MEN 2.
  • Side Effects: May include transient nausea, mild GI distress, or minor elevation in heart rate due to glucagon activity.
  • Child Safety: Keep out of reach of children.

Related products